| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 1.00 [0.80, 1.25] | | < 1 | | 0% | 2 studies (2/-) | 50.0 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 1.31 [1.05, 1.62] | | < 1 | | 0% | 2 studies (2/-) | 0.7 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 1.13 [0.32, 4.04] | | > 1 | | 0% | 2 studies (2/-) | 57.6 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.96 [0.39, 2.38] | | < 1 | | 0% | 2 studies (2/-) | 53.1 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 0.63 [0.19, 2.11] | | < 1 | | 88% | 2 studies (2/-) | 77.4 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 0.78 [0.18, 3.38] | | < 1 | | 0% | 2 studies (2/-) | 63.0 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.23 [0.23, 6.60] | | < 1 | | 79% | 2 studies (2/-) | 40.6 % | some concern | not evaluable | moderate | non important | - |
| SAE (any grade) | 1.28 [0.40, 4.10] | | < 1 | | 83% | 2 studies (2/-) | 34.0 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 1.41 [0.35, 5.60] | | < 1 | | 78% | 2 studies (2/-) | 31.4 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.18 [0.01, 2.73] | | < 1 | | 89% | 2 studies (2/-) | 88.9 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.32 [0.05, 2.26] | | < 1 | | 94% | 2 studies (2/-) | 87.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 0.71 [0.10, 5.06] | | < 1 | | 0% | 2 studies (2/-) | 63.5 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Dyspnoea TRAE (grade 3-4) | 0.89 [0.08, 9.99] | | < 1 | | 0% | 1 study (1/-) | 53.6 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.37 [0.24, 7.75] | | < 1 | | 0% | 2 studies (2/-) | 36.0 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 1.61 [0.14, 18.49] | | < 1 | | 0% | 2 studies (2/-) | 35.2 % | some concern | not evaluable | moderate | non important | - |
| Abdominal pain AE (grade 3-4) | 0.64 [0.16, 2.54] | | < 1 | | 27% | 2 studies (2/-) | 73.6 % | some concern | not evaluable | moderate | non important | - |
| Acute kidney injury AE (grade 3-4) | 0.63 [0.04, 10.13] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
| Anaemia AE (grade 3-4) | 1.06 [0.12, 9.33] | | < 1 | | 44% | 2 studies (2/-) | 47.9 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia AE (grade 3-4) | 0.31 [0.03, 3.47] | | < 1 | | 0% | 2 studies (2/-) | 82.6 % | some concern | not evaluable | moderate | non important | - |
| Asthenia AE (grade 3-4) | 2.50 [0.51, 12.27] | | < 1 | | 0% | 2 studies (2/-) | 13.0 % | some concern | not evaluable | moderate | non important | - |
| Back pain AE (grade 3-4) | 2.17 [0.20, 23.63] | | < 1 | | 0% | 2 studies (2/-) | 26.4 % | some concern | not evaluable | moderate | non important | - |
| Colitis AE (grade 3-4) | 1.79 [0.18, 17.83] | | < 1 | | 0% | 2 studies (2/-) | 31.1 % | some concern | not evaluable | moderate | non important | - |
| Constipation AE (grade 3-4) | 0.89 [0.07, 11.69] | | < 1 | | 0% | 2 studies (2/-) | 53.5 % | some concern | not evaluable | moderate | non important | - |
| Cough AE (grade 3-4) | 0.63 [0.04, 10.13] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite AE (grade 3-4) | 0.36 [0.07, 1.91] | | < 1 | | 0% | 2 studies (2/-) | 88.4 % | some concern | not evaluable | moderate | non important | - |
| Dermatitis acneiform AE (grade 3-4) | 1.37 [0.12, 15.71] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea AE (grade 3-4) | 0.69 [0.07, 7.10] | | < 1 | | 74% | 2 studies (2/-) | 62.3 % | some concern | not evaluable | moderate | non important | - |
| Dysgeusia AE (grade 3-4) | 0.89 [0.07, 11.69] | | < 1 | | 0% | 2 studies (2/-) | 53.5 % | some concern | not evaluable | moderate | non important | - |
| Dysphonia AE (grade 3-4) | 0.63 [0.04, 10.13] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea AE (grade 3-4) | 0.44 [0.01, 13.33] | | < 1 | | 0% | 1 study (1/-) | 67.8 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.54 [0.25, 1.19] | | < 1 | | 0% | 2 studies (2/-) | 93.8 % | some concern | not evaluable | moderate | non important | - |
| Guillain-Barré syndrome AE (grade 3-4) | 0.89 [0.07, 11.69] | | < 1 | | 0% | 2 studies (2/-) | 53.5 % | some concern | not evaluable | moderate | non important | - |
| Headache AE (grade 3-4) | 0.89 [0.07, 11.69] | | < 1 | | 0% | 2 studies (2/-) | 53.5 % | some concern | not evaluable | moderate | non important | - |
| Hypertension AE (grade 3-4) | 0.15 [0.05, 0.44] | | < 1 | | 13% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT AE (grade 3-4) | 0.31 [0.03, 3.47] | | < 1 | | 0% | 2 studies (2/-) | 82.6 % | some concern | not evaluable | moderate | non important | - |
| Infusion-related reaction AE (grade 3-4) | 1.37 [0.12, 15.71] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
| Intestinal perforation AE (grade 3-4) | 0.31 [0.03, 3.47] | | < 1 | | 0% | 2 studies (2/-) | 82.6 % | some concern | not evaluable | moderate | non important | - |
| Mucosal inflammation AE (grade 3-4) | 1.37 [0.12, 15.71] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
| Myalgia AE (grade 3-4) | 0.31 [0.03, 3.47] | | < 1 | | 0% | 2 studies (2/-) | 82.6 % | some concern | not evaluable | moderate | non important | - |
| Nausea AE (grade 3-4) | 1.37 [0.12, 15.71] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
| Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) | 0.03 [0.00, 0.24] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 0.31 [0.03, 3.47] | | < 1 | | 0% | 2 studies (2/-) | 82.6 % | some concern | not evaluable | moderate | non important | - |
| Peripheral oedema AE (grade 3-4) | 1.37 [0.12, 15.71] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis AE (grade 3-4) | 1.26 [0.11, 14.04] | | < 1 | | 0% | 2 studies (2/-) | 42.5 % | some concern | not evaluable | moderate | non important | - |
| Pruritus AE (grade 3-4) | 0.63 [0.04, 10.13] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia AE (grade 3-4) | 3.23 [0.32, 33.03] | | < 1 | | 0% | 2 studies (2/-) | 16.3 % | some concern | not evaluable | moderate | non important | - |
| Rash AE (grade 3-4) | 1.08 [0.28, 4.07] | | < 1 | | 0% | 2 studies (2/-) | 45.8 % | some concern | not evaluable | moderate | non important | - |
| Rash maculopapular AE (grade 3-4) | 0.44 [0.05, 3.83] | | < 1 | | 0% | 2 studies (2/-) | 76.9 % | some concern | not evaluable | moderate | non important | - |
| Sepsis AE (grade 3-4) | 0.36 [0.07, 1.91] | | < 1 | | 0% | 2 studies (2/-) | 88.4 % | some concern | not evaluable | moderate | non important | - |
| Stomatitis AE (grade 3-4) | 0.63 [0.04, 10.13] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.89 [0.07, 11.69] | | < 1 | | 0% | 2 studies (2/-) | 53.5 % | some concern | not evaluable | moderate | non important | - |
| Vomiting AE (grade 3-4) | 0.89 [0.07, 11.69] | | < 1 | | 0% | 2 studies (2/-) | 53.5 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased AE (grade 3-4) | 0.63 [0.04, 10.13] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
